1. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge
- Author
-
Sandrine Soman, Shelly J. Krebs, Diane L. Bolton, Gregory D. Gromowski, Ines Lakhal-Naouar, Swagata Kar, Michelle Zemil, Linda L. Jagodzinski, Amy R. Henry, Robert A. Seder, Lindsay Wieczorek, Hannah Grove, Dominic Paquin-Proulx, Adrienne Winn, Daniel C. Douek, Holly R. Hack, Caitlin Kuklis, Kamil Radzyminski, Rafael De La Barrera, Matthew Gagne, Caroline E. Peterson, James F. Wood, Heather Hernandez, Alexander R. A. Anderson, Xiankun Zeng, Stasya Zarling, Wei-Hung Chen, Mark G. Lewis, Rajeshwer S. Sankhala, Prakriti Mudvari, Andrew Pekosz, Victoria R. Polonis, Maciel Porto, Mangala Rao, Paul V. Thomas, Eli Boritz, M. Gordon Joyce, Sheila A. Peel, Elham Bayat Mokhtari, Kathryn McGuckin Wuertz, Nelson L. Michael, Sharon P. Daye, Akshaya Ganesh, Agnes Hajduczki, Gary R. Matyas, Jeffrey W. Froude, Vincent Dussupt, Erica K. Barkei, Kayvon Modjarrad, Jeffrey R. Currier, Sandhya Vasan, Janice Darden, Isabella Swafford, Elizabeth J. Martinez, Mehul S. Suthar, and Ming Dong
- Subjects
Protein vaccines ,Immunology ,Article ,Virus ,Medicine ,Pharmacology (medical) ,Neutralizing antibody ,RC254-282 ,Pharmacology ,biology ,SARS-CoV-2 ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC581-607 ,QS21 ,Virology ,Ferritin ,Vaccination ,Infectious Diseases ,Viral replication ,Viral infection ,biology.protein ,Nasal administration ,Immunologic diseases. Allergy ,business ,Viral load - Abstract
The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the Alpha (B.1.1.7), and Beta (B.1.351) VOCs in Syrian golden hamsters. SpFN-ALFQ was administered as either single or double-vaccination (0 and 4 week) regimens, using a high (10 μg) or low (0.2 μg) dose. Animals were intranasally challenged at week 11. Binding antibody responses were comparable between high- and low-dose groups. Neutralizing antibody titers were equivalent against WA1, B.1.1.7, and B.1.351 variants following two high dose vaccinations. Dose-dependent SpFN-ALFQ vaccination protected against SARS-CoV-2-induced disease and viral replication following intranasal B.1.1.7 or B.1.351 challenge, as evidenced by reduced weight loss, lung pathology, and lung and nasal turbinate viral burden. These data support the development of SpFN-ALFQ as a broadly protective, next-generation SARS-CoV-2 vaccine.
- Published
- 2021